Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Overview

The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 23, 2021

Detailed Description

Plan: We will perform a randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for LID in PD. Methods: Eligible subjects who consent to participate in this study will be randomized to one of two sequences of treatment interventions during the baseline visit. Each treatment sequence includes placebo and buspirone interventions. After randomization, each participant will titrate up on study drug for two weeks ending in 30 mg/day. At the end of each two week study drug period, the participant will then have a study visit at the VA Portland Health Care System that includes safety monitoring, adverse event monitoring, drug compliance, and several measurements of LID.

Interventions

  • Drug: Buspirone
  • Drug: Placebo
    • Sugar Pill

Arms, Groups and Cohorts

  • Experimental: Buspirone
    • Two week titration up to 10 mg tablet/3 times a day for 7 days
  • Placebo Comparator: Placebo
    • Two week titration up to 3 tablets/3 times a day for 7 days

Clinical Trial Outcome Measures

Primary Measures

  • Area Under the Curve – Dyskinesia – Forceplate
    • Time Frame: 6 hour levodopa dose cycle
    • forceplate measurements of levodopa induced dyskinesia taken every 1/2 hour for 6 hours.
  • Dyskinesia – UDysRS
    • Time Frame: up to 6 weeks
    • UDysRS total score comparison
  • Adverse Events
    • Time Frame: up to 6 weeks
    • Adverse Events Monitoring/Frequency

Participating in This Clinical Trial

Inclusion Criteria

  • Parkinson's disease diagnosis – Currently taking a levodopa containing medication for Parkinson's disease – Mild to Severe dyskinesia – Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia. – Stable medication regimen for at least 4 weeks prior to study. Exclusion Criteria:

  • Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation. – Not able to follow verbal commands – Not able to stand unsupported for at least 60 seconds – Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia. – Have proprioceptive deficits. – Have a history of hepatic impairment – Currently have severe renal impairment – Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study. – Significant cognitive impairment – Pregnancy – Breast-Feeding – Unable to swallow study drug (capsule)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oregon Health and Science University
  • Collaborator
    • Portland VA Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kathryn Anne Chung, Associate Professor – Neurology – Oregon Health and Science University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.